@misc{oai:repo.qst.go.jp:00066981,
 author = {関, 千江 and 服部, 靖志 and 前田, 純 and 永井, 裕司 and 内田, 翔子 and 徳永, 正希 and 張, 明栄 and 小池竜樹 and 樋口, 真人 and 関 千江 and 服部 靖志 and 前田 純 and 永井 裕司 and 内田 翔子 and 徳永 正希 and 張 明栄 and 樋口 真人},
 month = {Nov},
 note = {Introduction Monoacylglycerol lipase (MAGL) is considered as a novel therapeutic target of CNS disorders. [18F]T-401 has been developed as a reversible and selective PET imaging agent. The aim of this study was to test the capability of [18F]T-401 for imaging MAGL in rat and monkey brains. 
Methods In vitro ARG was performed to evaluate [18F]T-401 binding to MAGL. [18F]T-401-PET imaging was conducted with and without pre-treatments with unlabeled T-401 and several doses of an MAGL inhibitor, JW642.
Results ARG and PET demonstrated specific [18F]T-401 binding corresponding to MAGL distribution. [18F]T-401 kinetics was reversible and enabled estimation of total distribution volume (VT) in monkey brains. Pretreatment of monkeys with JW642 reduced VT values in a dose-dependent manner. Conclusion The current observations support the utility of [18F]T-401 for quantitative PET evaluation of MAGL., 第58回日本核医学会学術総会に参加し武田薬品との共同研究成果を発表},
 title = {新規モノアシルグリセロールリパーゼPETリガンド[18F]T-401の前臨床評価},
 year = {2018}
}